PainReform (PRFX) Stock Price, News & Analysis

Company Overview

PainReform Ltd. is a clinical-stage specialty pharmaceutical company focused on developing treatments for acute post-operative pain. The company’s goal is to provide longer-lasting pain relief at the surgical site while potentially reducing reliance on opioid medications after surgery.

PainReform’s lead product candidate, PRF-110, is an investigational extended-release formulation of the local anesthetic ropivacaine. The product is designed to be administered directly into a surgical site and provide pain relief for up to approximately 72 hours following a procedure. PainReform has evaluated PRF-110 in clinical studies involving surgical patients, including procedures such as bunion surgery.

The company was founded in Israel and conducts its development activities in support of potential commercialization in international markets, including the United States. PRF-110 remains an investigational product and is subject to clinical, regulatory and manufacturing requirements before it can be marketed.

Key Stats

• Today's Range: $0.85 to $0.89
• 50-Day Range: $0.86 to $1.20
• 52-Week Range: $0.85 to $7.95
• Volume: 31,764 shs
• Average Volume: 368,971 shs
• Market Capitalization: $764.64 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

PainReform Stock Analysis - MarketRank™

PainReform scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

PainReform has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

PainReform has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of PainReform is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of PainReform is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

PainReform has a P/B Ratio of 0.04. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.85% of the float of PainReform has been sold short.

Short Interest Ratio / Days to Cover

PainReform has a short interest ratio ("days to cover") of 0.04, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in PainReform has recently decreased by 59.66%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PainReform does not currently pay a dividend.

Dividend Growth

PainReform does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.92

News Sentiment

PainReform has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for PainReform this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, PainReform insiders have not sold or bought any company stock.

Percentage Held by Insiders

34.40% of the stock of PainReform is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

37.28% of the stock of PainReform is held by institutions.

Company Calendar

• Last Earnings: 9/03/2026
• Today: 10/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:PRFX
• CIK: 1801834
• Web: www.painreform.com
• Phone: 972-3717-7051
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.07
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $20 thousand
• Price / Sales: 38.23
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $23.07 per share
• Price / Book: 0.04

Miscellaneous

• Outstanding Shares: 870,000
• Free Float: 570,000
• Market Cap: $764.64 thousand
• Optionable: Not Optionable
• Beta: 1.08